SANTA FE, N.M.--(BUSINESS WIRE)--The following is an opinion editorial provided by Allen D. Allen, CEO, CytoDyn, Inc.: As reported by AIDS Treatment News on December 31, 2009, CytoDyn, Inc. (Pink Sheets: CYDY) has entered into an Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital for a clinical trial of Cytolin®, our Company’s novel immune therapy for treating HIV/AIDS. The Agreement between CytoDyn and Massachusetts General Hospital takes a different approach to new drug development that merges elements of the private and public sectors. CytoDyn believes this approach is superior to the standard modalities because it can provide:
